TNF and melanoma: At functional level, we showed an impaired secretion of TNFα by both CD117- ILCs and CD117+ ILCs from melanoma patients, as reported in blood tumors (17, 18), and the capability of Nivolumab to enhance the secretion of IL-13 and TNFα by ILC2s and CD117+ ILCs, respectively.